Fig. 1.
Kaplan-Meier plot for progression-free survival and overall survival of patients with advanced or recurrent uterine carcinosarcoma receiving pembrolizumab and lenvatinib combination therapy.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.